Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
-
REGULATORY Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
-
BUSINESS Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
February 19, 2026
-
BUSINESS ONODERA GT Pharma Targets 2026 Filings for Two Gene Therapies
February 19, 2026
-
COMMENTARY Hisamitsu’s MBO: Is Shareholder Accountability Trust-Building or a Shackle?
February 18, 2026
-
BUSINESS Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
-
BUSINESS Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
-
REGULATORY 10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
-
REGULATORY MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
-
REGULATORY Japan Panel to Review Sumitomo, Cuorips iPSC Products on Feb. 19
February 16, 2026
-
REGULATORY DMD Gene Therapy Elevidys Cleared for NHI Listing at 305 Million Yen
February 13, 2026
-
BUSINESS FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
-
BUSINESS Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
-
BUSINESS Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
-
REGULATORY LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
-
COMMENTARY Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision
February 9, 2026
-
ORGANIZATION Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
-
BUSINESS Lilly Discloses Japan Filing for Orforglipron, Starting with Obesity
February 6, 2026
-
BUSINESS Ono Recalls Certain Opdivo Lots over Possible Metal Contamination
February 6, 2026
-
COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key
February 5, 2026
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…